Given that AML has been shown to harbour dynamic clonal evolution at relapse, including the addition of new mutations that could be relevant for relapse pathogenesis [92], evaluating the MTF2 modifications at this stage of disease would be worthwhile to explore. Here, MTF2 is linked to acute myeloid leukemia.